Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 16327325)

1.
2.

Costing of scaling up HIV/AIDS treatment in Mexico.

Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM.

Salud Publica Mex. 2008;50 Suppl 4:S437-44.

3.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

Sánchez-de la Rosa R, Herrera L, Moreno S.

Clin Ther. 2008 Feb;30(2):372-81. doi: 10.1016/j.clinthera.2008.02.009.

PMID:
18343275
4.

The economics of effective AIDS treatment in Thailand.

Over M, Revenga A, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S.

AIDS. 2007 Jul;21 Suppl 4:S105-16.

PMID:
17620745
5.

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.

Antivir Ther. 2004 Feb;9(1):27-36.

PMID:
15040534
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.
8.

[Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil].

Acurcio Fde A, Puig-Junoy J, Bonolo Pde F, Braga Ceccato Md, Guimarães MD.

Rev Esp Salud Publica. 2006 Jan-Feb;80(1):41-54. Spanish.

PMID:
16553259
9.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):499-508.

PMID:
10221527
10.

Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.

Caro JJ, O'Brien JA, Migliaccio-Walle K, Raggio G.

Pharmacoeconomics. 2001 Jan;19(1):95-104.

PMID:
11252549
11.

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000.

PMID:
21182345
12.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;3:CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540
13.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
14.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
15.

[Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].

García-Ramos SE, Santolaya Perrín MR, Fernández-Pacheco García-Valdecasas M.

Farm Hosp. 2012 Sep-Oct;36(5):315-20. doi: 10.1016/j.farma.2011.03.006. Epub 2012 Jul 31. Spanish.

PMID:
22858089
16.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

17.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
18.
19.

Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.

Dhamija P, Bansal D, Medhi B.

Curr HIV Res. 2009 Jul;7(4):410-7.

PMID:
19601776
20.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk